ERIC JONASCH to Programmed Cell Death 1 Receptor
This is a "connection" page, showing publications ERIC JONASCH has written about Programmed Cell Death 1 Receptor.
Connection Strength
0.150
-
Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. Cancer Med. 2021 04; 10(7):2341-2349.
Score: 0.121
-
Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. Cancer Cell. 2020 03 16; 37(3):371-386.e12.
Score: 0.028